Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/33827
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRamírez, Elena
dc.contributor.authorMedrano-Casique, Nicolás
dc.contributor.authorTong, Hoi Y
dc.contributor.authorBellón, Teresa
dc.contributor.authorCabañas, Rosario
dc.contributor.authorFiandor, Ana
dc.contributor.authorGonzález-Ramos, Jessica
dc.contributor.authorHerranz, Pedro
dc.contributor.authorTrigo, Elena
dc.contributor.authorMuñoz, Mario
dc.contributor.authorBorobia, Alberto M
dc.contributor.authorCarcas, Antonio J
dc.contributor.authorFrías, Jesús
dc.date.accessioned2019-06-28T17:24:13Z-
dc.date.available2019-06-28T17:24:13Z-
dc.date.issued2017
dc.identifier.citationBr J Clin Pharmacol.2017 02;(83)2:400-415
dc.identifier.urihttps://hdl.handle.net/20.500.12530/33827-
dc.description.abstractWe conducted a prospective evaluation of all eosinophilic drug reactions (EDRs) through the Prospective Pharmacovigilance Program from Laboratory Signals at Hospital to find out the incidence and distribution of these entities in our hospital, their causative drugs, and predictors.
dc.language.isoeng
dc.rightsopenAccess-
dc.subjectadverse drug reaction
dc.subjectdrug-induced
dc.subjecteosinophilia
dc.subjecteosinophilic drug reactions
dc.subjectpharmacovigilance
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshChild
dc.subject.meshChild, Preschool
dc.subject.meshDrug Eruptions
dc.subject.meshDrug Hypersensitivity Syndrome
dc.subject.meshDrug-Related Side Effects and Adverse Reactions
dc.subject.meshEosinophilia
dc.subject.meshFemale
dc.subject.meshHospitalization
dc.subject.meshHumans
dc.subject.meshIncidence
dc.subject.meshInfant
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshProspective Studies
dc.subject.meshSeverity of Illness Index
dc.subject.meshTertiary Care Centers
dc.subject.meshYoung Adult
dc.subject.meshPharmacovigilance
dc.titleEosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital.
dc.typeArtículo
dc.identifier.pubmedID27543764
dc.format.volume83
dc.format.page400-415
dc.identifier.e-issn1365-2125
dc.identifier.journalBritish journal of clinical pharmacology
dc.identifier.doi10.1111/bcp.13096
dc.format.number2
dc.identifier.pmcPMC5237701
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos
Hospitales > H. U. La Paz > Artículos

Files in This Item:
File Description SizeFormat 
PMC5237701.pdf1.04 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.